Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Overview of attention for article published in New England Journal of Medicine, September 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 30 news outlets
blogs: 3 blogs
twitter: 169 X users
video: 1 YouTube creator

guideline: 4 clinical guideline sources
bluesky: 2 Bluesky users
podcasts: 4 podcasts

Readers on

mendeley: 228 Mendeley

So far, Altmetric has seen 195 X posts from 169 X users, with an upper bound of 1,633,419 followers.

Source: NIAGARA (Powles et al., NEJM 2024) - https://t.co/K7CQbolYzl

RT @dr_yakupergun: Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer NIAGARA trial EFS and OS ✅️ https:…

RT @DrChoueiri: JUST IN (again): @US_FDA approved Durvalumab for the Neoadjuvant treatment of muscle-invasive bladder cancer based on the #…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 191 additional X posts.